Founded in 2014, Shenzhen TargetRx, Inc. (hereinafter referred to as "TargetRx") is a Sino-US joint venture, high-tech pharmaceutical R&D company. Since its establishment, TargetRx has received investments from many well-known domestic investment institutions. TargetRx focuses on the R&D of the new frontier in targeted cancer therapies, aiming at addressing urgent clinical needs through the emerging development of next-generation small-molecule targeted drugs against cancer. We conduct comprehensive drug design and screening research to evaluate and optimize the novel compounds with independent intellectual property rights. Accumulatively, more than 200 inventions have been patented in China, US, Europe, Japan, etc. At present, TargetRx's two flagship products, the next-generation Bcr-Abl allosteric inhibitor TGRX-678 with a novel mechanism for the treatment of chronic myelogenous leukemia (CML), and the third-generation ALK inhibitor TGRX-326 for the treatment of non-small cell lung cancer (NSCLC) have both conducted the dosing of first subject in Phase I studies. At the same time, other research projects of TargetRx are also in progress. TargetRx is committed to making tremendous progress in treating cancer - overcoming acquired resistance, such that cancer could be transformed from a rapidly and inevitably fatal disease into a condition that can be acceptably managed over time.
